TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03777306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARM A EARLY INTERVENTION GROUP
Description: Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~* 1 video/picture/worksheet per week covering the topic to be covered.~* 1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~* 3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARM B DELAYED INTERVENTION GROUP
Description: The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
Study: NCT02002598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 \| 60 mg/m2~1. \| 70 mg/m2~2. \| 70 mg/m2~3. \| 90 mg/m2~4. \| 90mg/m2~5. \| 90 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 \| 27 mg/m2~1. \| 27 mg/m2~2. \| 36 mg/m2~3. \| 36 mg/m2~4. \| 45 mg/m2~5. \| 56 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
Study: NCT02202122

Intervention type: OTHER
Intervention: OSA Scoring
Description: Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
Study: NCT03542812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
Study: NCT02977663

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: * Chest MRI during the MRI cerebral~* 2 tubes of blood taken during the medical visit
Study: NCT04305834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study: NCT04555031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A lenses
Description: Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dalies Total 1
Description: Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision 1
Description: Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotrue ONEday
Description: Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
Study: NCT01422421

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intensive control
Description: use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard control
Description: use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
Study: NCT02805881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurolief system
Description: Non-invasive cephalic neurostimulation device
Study: NCT03368638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Description: Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
Study: NCT03463161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat (100mg) taken by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat (100mg) taken by mouth twice a day.
Study: NCT05132192

Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: Living donor liver transplantation

Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: Living donor liver transplantation

Intervention type: PROCEDURE
Intervention: Thrombectomy or interposition graft
Description: Portal flow restoration due to PVT in any manner
Study: NCT02372136

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized Nutrition
Description: Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optimized nutrition
Description: Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Optimized nutrition
Description: Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
Study: NCT02704468

Intervention type: OTHER
Intervention: CAVI and FGF-21
Description: FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
Study: NCT02075541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHi-10-AS01E
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl Placebo
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study: NCT01964885

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IQP-AS-105

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04305834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03269422

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-based image-guided, intensity-modulated radiotherapy
Description: Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
Study: NCT02252380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExAblate System
Description: MR Guided Focused Ultrasound
Study: NCT02168868

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A blood sample (5 mL) will be collected.
Study: NCT05235204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of Foley Catheter 2 to 3 days post Colovesical Fistula (CVF) repair surgery
Description: According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
Study: NCT03954795

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP
Description: Classic TAP block performed through the petit triangle (the anterior axillary line and iliac crest)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OSTAP
Description: Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
Study: NCT04466995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manometer
Description: cuff pressure to be measured with manometer

Intervention type: DEVICE
Group type: OTHER
Intervention: manometer
Description: cuff pressure to be measured with manometer
Study: NCT02168868

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A blood sample (5 mL) will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A blood sample (5 mL) will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A blood sample (5 mL) will be collected.
Study: NCT01088828

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of calf and foot
Description: Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of calf and foot
Description: Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of calf and foot
Description: Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of calf and foot
Description: Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of calf and foot
Description: Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
Study: NCT02168868

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A blood sample (5 mL) will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A blood sample (5 mL) will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample Collection
Description: Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample Collection
Description: Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample Collection
Description: Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample Collection
Description: Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample Collection
Description: Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.
Study: NCT01632670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
Study: NCT03698812

Intervention type: COMBINATION_PRODUCT
Intervention: Colonoscope
Description: take off specimen

Intervention type: COMBINATION_PRODUCT
Intervention: Colonoscope
Description: take off specimen
Study: NCT00974376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1200mg/day
Description: gabapentin 1200mg/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1200mg/day of placebo for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
Study: NCT04230187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI plus Bevacizumab
Description: Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 Plus Bevacizumab
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
Study: NCT03341689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Psilocybin
Description: 0.143 mg/kg psilocybin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Psilocybin
Description: 0.143 mg/kg psilocybin capsule
Study: NCT04410991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide HMR1726
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match Tolebrutinib
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Teriflunomide
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study: NCT03341689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.0143 mg/kg psilocybin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.0143 mg/kg psilocybin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: microcrystalline cellulose capsule
Study: NCT01668901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: anticoagulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: antiplatelet
Study: NCT02762149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve stimulator
Description: The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve stimulator
Description: The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
Study: NCT03107832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural anesthesia procedure
Description: general anesthesia procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic epidural anesthesia procedure
Description: general anesthesia procedure
Study: NCT02547259

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pain words test
Description: words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain words test
Description: words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: negative words test
Description: words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: negative words test
Description: words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word.
Study: NCT02374671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisAbility Micro Insert
Description: Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisAbility Micro Insert
Description: Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
Study: NCT03581825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Multifocal
Description: JJVC Investigational Multifocal Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Multifocal
Description: JJVC Investigational Multifocal Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Sphere
Description: ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Sphere
Description: ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Multifocal
Description: 1-Day Acuvue Moist Brand Multifocal Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Multifocal
Description: 1-Day Acuvue Moist Brand Multifocal Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Sphere
Description: 1-Day Acuvue Moist Brand Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Sphere
Description: 1-Day Acuvue Moist Brand Contact Lens